(NASDAQ: ALT) Altimmune's forecast annual revenue growth rate of 1,505.87% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Altimmune's revenue in 2025 is $20,000.On average, 1 Wall Street analysts forecast ALT's revenue for 2025 to be $15,402,731,600, with the lowest ALT revenue forecast at $15,402,731,600, and the highest ALT revenue forecast at $15,402,731,600. On average, 2 Wall Street analysts forecast ALT's revenue for 2027 to be $6,378,656,224, with the lowest ALT revenue forecast at $2,849,505,346, and the highest ALT revenue forecast at $9,907,807,102.
In 2028, ALT is forecast to generate $36,176,780,777 in revenue, with the lowest revenue forecast at $2,043,942,483 and the highest revenue forecast at $126,059,035,961.